The C12ORF5 gene was discovered in the early 2000s and has since been studied extensively. The protein encoded by this gene is known as TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator). TIGAR is a newly discovered enzyme that largely regulates glucose breakdown in human cells . The protein has a tertiary structure similar to the histidine phosphatase fold and is approximately 30 kDa in size. The core of TIGAR is a β-sandwich composed of a six-stranded β-sheet encircled by four α-helices .
TIGAR plays a crucial role in cellular metabolism by regulating the levels of fructose-2,6-bisphosphate, a key regulator of glycolysis. By lowering the levels of fructose-2,6-bisphosphate, TIGAR inhibits glycolysis and promotes the pentose phosphate pathway, which is essential for generating NADPH and ribose-5-phosphate . This shift in metabolic pathways helps cells to manage oxidative stress and repair DNA damage.
Additionally, TIGAR has the ability to protect cells from apoptosis (programmed cell death) induced by oxidative stress. This protective function is particularly important in cancer cells, where TIGAR activity can contribute to tumor survival and growth .
The p53 tumor suppressor protein, which is activated in response to DNA damage, induces the expression of TIGAR. This connection between p53 and TIGAR has made the C12ORF5 gene a target of interest in cancer research. Studies have shown that TIGAR is overexpressed in various types of cancer, including breast, liver, and colorectal cancers . The overexpression of TIGAR in cancer cells helps them to survive under conditions of metabolic stress and contributes to their resistance to chemotherapy.
Researchers are exploring the potential of targeting TIGAR as a therapeutic strategy for cancer treatment. By inhibiting TIGAR activity, it may be possible to sensitize cancer cells to chemotherapy and reduce their ability to survive under metabolic stress .